Divi's Laboratories Limited (NSE:DIVISLAB)

Market Cap	1.58T
Revenue (ttm)	90.78B
Net Income (ttm)	20.67B
Shares Out	265.47M
EPS (ttm)	77.84
PE Ratio	76.57
Forward PE	66.29
Dividend	30.00 (0.50%)
Ex-Dividend Date	Aug 2, 2024

Volume	449,981
Average Volume	612,721
Open	5,841.50
Previous Close	5,960.50
Day's Range	5,841.50 - 6,055.50
52-Week Range	3,724.00 - 6,308.50
Beta	0.28
RSI	51.74
Earnings Date	May 23, 2025

About Divi's Laboratories

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It al...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 9,741
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: DIVISLAB

Financial Performance

In 2023, Divi's Laboratories's revenue was 78.45 billion, an increase of 1.00% compared to the previous year's 77.67 billion. Earnings were 16.00 billion, a decrease of -12.28%.